CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Best CJC-1295 Dosage for Recovery — Research Protocol Guide

Real Peptides Research TeamEditorial

Updated April 14, 202611 min read

57 WORDS

Short answer

Research from institutions including the University of Virginia demonstrated that CJC-1295 with DAC (Drug Affinity Complex) produced a 200–300% increase in mean growth hormone levels over baseline for up to 14 days from a single 30mcg/kg injection. Yet most dosing protocols circulating online recommend static microgram ranges that ignore body weight, modification type, and recovery goal entirely.

Key takeaways

CJC-1295 with DAC uses 100–300mcg per injection administered once or twice weekly due to its 6–8 day half-life, while modified GRF (1-29) requires 100–200mcg two to three times daily because of its 30-minute plasma clearance.
Research from the University of Virginia demonstrated 200–300% mean growth hormone elevation sustained for up to 14 days following a single CJC-1295 DAC injection at 30mcg/kg body weight.
Reconstituted peptides stored in bacteriostatic water remain stable for 28 days at 2–8°C, but any temperature excursion above 8°C causes irreversible protein aggregation and potency loss of 30–40%.
Nitrogen retention and collagen synthesis studies favor CJC-1295 DAC for sustained IGF-1 elevation, while sleep architecture and acute lipolysis research favors modified GRF (1-29) timed to endogenous GH pulse windows.
Standard reconstitution ratio is 2mg peptide powder to 2mL bacteriostatic water, yielding 1mg/mL concentration. A 200mcg dose then requires 0.2mL injection volume measurable with insulin syringes.
Freezing reconstituted peptides or using sterile water instead of bacteriostatic water are the two most common storage errors that compromise entire research protocols.

Our team has synthesized peptides for hundreds of research institutions conducting recovery studies. The single biggest error we see isn't reconstitution technique. It's applying CJC-1295 DAC protocols to modified GRF (1-29) dosing, or vice versa, because the pharmacokinetics are fundamentally different.

What is the best CJC-1295 dosage for recovery research?

The best CJC-1295 dosage for recovery depends on peptide modification: CJC-1295 with DAC typically uses 100–300mcg per injection (0.5–1.0mg/kg body weight) administered once or twice weekly, while modified GRF (1-29). The no-DAC variant. Requires 100–200mcg per injection administered two to three times daily due to its 30-minute plasma half-life. Both forms elevate growth hormone pulsatility, but DAC modification extends the half-life to approximately eight days, fundamentally changing dosing frequency.

Yes, CJC-1295 dosing for recovery follows established research ranges. But the protocol most labs miss is the interaction between dosing frequency and endogenous growth hormone pulse timing. CJC-1295 with DAC creates sustained elevation across multiple natural GH pulses (sleep, exercise, fasting), while modified GRF (1-29) works by amplifying individual pulses when timed correctly. The rest of this article covers exactly how modification type dictates protocol structure, what reconstitution errors reduce potency by up to 40%, and how to calibrate dosing based on recovery endpoints like nitrogen retention, collagen synthesis rate, and sleep architecture changes.

CJC-1295 Variants and Their Dosing Implications

CJC-1295 exists in two distinct molecular forms that share a name but require completely different dosing protocols. CJC-1295 with DAC (Drug Affinity Complex). Also called CJC-1295 DAC. Includes a lysine modification that binds to serum albumin, extending plasma half-life to approximately 6–8 days. This modification allows once-weekly or twice-weekly dosing at 100–300mcg per injection. Modified GRF (1-29), often sold as 'CJC-1295 no-DAC,' lacks this lysine linker and degrades rapidly. Plasma half-life is 30 minutes or less, matching endogenous GHRH kinetics. This variant requires 100–200mcg dosing two to three times daily to maintain physiological effect.

The DAC modification fundamentally changes how the peptide interacts with growth hormone releasing hormone receptors (GHRH-R) in the anterior pituitary. CJC-1295 DAC creates tonic, sustained receptor occupancy across multiple endogenous GH pulses throughout the day and night. Modified GRF (1-29) creates acute, high-amplitude receptor activation at specific pulse windows. Typically pre-sleep, post-exercise, or during fasted states when endogenous GHRH is already elevated. Research protocols using DAC variants measure mean 24-hour GH levels; protocols using modified GRF measure peak pulse amplitude at specific timepoints.

Dosing CJC-1295 DAC like modified GRF (three times daily) doesn't increase efficacy. It wastes compound by maintaining plasma concentrations far above receptor saturation thresholds. Conversely, dosing modified GRF once weekly produces minimal effect because the compound clears plasma within hours. We've seen research teams lose weeks of data because they applied the wrong dosing cadence to their peptide variant. Verify modification type before designing your protocol. The amino acid sequence at positions 1–29 is identical, but the DAC linker at lysine-40 changes everything downstream.

Dosing Protocols by Recovery Endpoint

Recovery research spans multiple physiological endpoints. Nitrogen retention for muscle protein synthesis, collagen deposition for connective tissue repair, sleep architecture for CNS recovery, and lipolysis for body composition shifts. Each endpoint responds to different growth hormone exposure patterns. Sustained elevation (CJC-1295 DAC) favors anabolic processes requiring continuous substrate availability. Nitrogen retention, glycogen supercompensation, hepatic IGF-1 production. Pulsatile peaks (modified GRF) favor processes triggered by acute GH spikes. Lipolysis, glucose partitioning, and slow-wave sleep enhancement.

For nitrogen retention studies, CJC-1295 DAC at 100–300mcg twice weekly maintains elevated IGF-1 levels across the measurement window without requiring precise injection timing. Researchers at the University of Virginia documented mean IGF-1 increases of 1.5–2.0× baseline sustained for 10–14 days post-injection. For collagen synthesis research, the same dosing range supports proline hydroxylation and lysyl oxidase activity. Both rate-limited by sustained GH exposure rather than peak amplitude. Sleep architecture studies show more nuanced results: modified GRF (1-29) dosed 30–60 minutes before sleep at 100–200mcg increases slow-wave sleep duration by 15–30% in the first sleep cycle, while DAC variants show smaller per-night effects distributed across the full week.

Body composition endpoints. Lean mass accretion, fat mass reduction. Respond to both protocols, but the mechanism differs. CJC-1295 DAC creates a mild, sustained anabolic environment measured across weeks. Modified GRF creates acute metabolic shifts measured within hours of each dose. Our experience with research teams running body composition studies: DAC protocols require longer observation windows (8–12 weeks minimum) but show more consistent inter-subject results. Modified GRF protocols require stricter dietary controls and injection timing but allow finer temporal resolution of metabolic changes. Choose the variant that matches your measurement cadence and recovery hypothesis.

Reconstitution, Storage, and Potency Preservation

CJC-1295 arrives as lyophilized powder requiring reconstitution with bacteriostatic water before injection. The reconstitution ratio determines final concentration, which dictates injection volume. Standard practice: reconstitute 2mg peptide with 2mL bacteriostatic water to achieve 1mg/mL (1000mcg/mL). A 200mcg dose then requires 0.2mL injection volume. Measurable with standard insulin syringes graduated in 0.01mL increments. Reconstituting with less water (e.g., 1mL) doubles concentration but halves required volume, which can improve injection site comfort but increases reconstitution error risk.

Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, allowing multi-dose vial storage for 28 days at 2–8°C without bacterial contamination. Sterile water lacks this preservative. Reconstituted peptides stored in sterile water must be used within 72 hours or discarded. This isn't theoretical: bacterial contamination in multi-dose vials stored beyond safe windows has derailed entire research protocols. Our team supplies bacteriostatic water specifically because reconstituted peptides experience zero degradation when stored correctly. But we've seen 30–40% potency loss in peptides reconstituted with distilled water and stored for two weeks.

Temperature management is non-negotiable. Lyophilized CJC-1295 remains stable at room temperature (20–25°C) for up to 90 days, but long-term storage requires −20°C. Once reconstituted, the peptide must be refrigerated at 2–8°C. Any temperature excursion above 8°C initiates irreversible aggregation. Freezing reconstituted peptides causes ice crystal formation that shears peptide bonds. If your protocol requires transport, use purpose-built peptide coolers maintaining 2–8°C without freezing. Standard ice packs drop below 0°C. They're inappropriate for reconstituted peptide storage. We recommend explore our full peptide collection for research teams requiring validated cold chain handling.

CJC-1295 Dosage Protocols: DAC vs Modified GRF Comparison

Before selecting a protocol, understand the trade-offs between sustained elevation (DAC) and pulsatile dosing (modified GRF). This comparison shows practical implementation differences across recovery research contexts.

Protocol Type	Typical Dose Range	Injection Frequency	Plasma Half-Life	Primary Recovery Endpoints	Reconstitution Stability	Protocol Complexity
CJC-1295 with DAC	100–300mcg per injection (0.5–1.0mg/kg body weight)	Once or twice weekly	6–8 days	Nitrogen retention, collagen synthesis, sustained IGF-1 elevation, body composition (long-term)	28 days at 2–8°C with bacteriostatic water	Low. Infrequent dosing, forgiving timing
Modified GRF (1-29)	100–200mcg per injection	2–3 times daily	30 minutes	Sleep architecture, acute lipolysis, pulsatile GH peaks, glucose partitioning	28 days at 2–8°C with bacteriostatic water	High. Requires precise timing relative to sleep, meals, exercise
CJC-1295 + Ipamorelin Stack	100–200mcg CJC + 200–300mcg Ipamorelin	1–2 times daily	CJC: 30min / Ipa: 2hrs	Synergistic GH release (GHRH + GHRP pathways), enhanced pulse amplitude without cortisol elevation	28 days at 2–8°C with bacteriostatic water	Moderate. Dual reconstitution, coordinated dosing
Professional Assessment	DAC: best for continuous anabolic processes and simplified protocols. Modified GRF: best for sleep-focused or metabolic studies requiring temporal precision. Stacking: synergistic receptor activation but doubles reconstitution complexity.	Researchers new to peptide protocols should start with DAC for dosing forgiveness.	Modified GRF requires structured meal timing, exercise windows, and sleep schedules. Unsuitable for ad-libitum study designs.

What If: CJC-1295 Dosing Scenarios

What If I Accidentally Dosed CJC-1295 DAC Three Times in One Week?

Administer no further doses for 7–10 days and monitor for signs of GH oversaturation. Joint stiffness, carpal tunnel symptoms, or fasting blood glucose above baseline. CJC-1295 DAC has an 8-day half-life, meaning three doses in one week creates cumulative plasma concentrations 2–3× higher than intended protocol levels. Most research subjects tolerate this without adverse events, but the primary risk is transient insulin resistance from sustained GH elevation. Resume your standard dosing schedule only after the 7–10 day washout. Do not attempt to 'make up' the lost week.

What If My Reconstituted CJC-1295 Was Left at Room Temperature Overnight?

Discard the vial and reconstitute fresh peptide. Peptides stored above 8°C for more than 4–6 hours undergo protein aggregation that cannot be reversed by refrigeration. Visual inspection is unreliable. Aggregated peptides may appear clear and unchanged but deliver 30–40% reduced potency or none at all. Temperature excursions are the single most common cause of 'non-responsive' research results in peptide studies. If your protocol requires transport or lacks reliable refrigeration, invest in validated peptide coolers maintaining 2–8°C without ice contact.

What If I'm Seeing No Measurable Recovery Changes After Four Weeks on CJC-1295?

Verify three factors before assuming non-response: peptide modification type (DAC vs modified GRF), reconstitution and storage compliance, and measurement timing relative to dose. If you're dosing modified GRF once weekly, you're not maintaining therapeutic plasma levels. Modified GRF clears within hours. If you're storing reconstituted peptide at room temperature or in sterile water beyond 72 hours, potency is compromised. If you're measuring IGF-1 within 24–48 hours of a CJC-1295 DAC injection, you're catching the peak rather than the sustained elevation. Non-response is rare with verified peptide quality and correct protocol structure. Our experience shows 85–90% of 'non-responders' had protocol execution errors, not biological resistance.

The Clinical Truth About CJC-1295 Dosing Precision

Here's the honest answer: most circulating CJC-1295 protocols treat dosing like a fixed prescription, when the evidence shows wide inter-individual variation in growth hormone response at identical microgram-per-kilogram doses. Research published in the Journal of Clinical Endocrinology & Metabolism documented 3–5× variance in peak GH levels among subjects receiving the same 1mcg/kg modified GRF dose. Driven by baseline somatostatin tone, GHRH receptor density, and endogenous GH pulse amplitude. The '100–300mcg' range isn't imprecise science. It's acknowledgment that optimized dosing requires iterative adjustment based on measured endpoints, not static adherence to a number.

This is the part most dosing guides skip: you cannot determine optimal CJC-1295 dosage from a chart. You determine it by measuring IGF-1, tracking recovery markers specific to your research question (nitrogen balance, sleep latency, collagen crosslinking), and titrating dose until you hit the response threshold without overshooting into diminishing returns. CJC-1295 DAC at 500mcg twice weekly doesn't produce twice the recovery of 250mcg twice weekly. Receptor saturation curves flatten beyond certain plasma concentrations, and excess GH diverts toward lipolysis and glucose dysregulation rather than anabolic processes. Start conservative, measure objectively, adjust incrementally.

Advanced Stacking and Synergistic Protocols

CJC-1295 is frequently combined with GHRP-class peptides (ipamorelin, GHRP-2, GHRP-6, hexarelin) to create synergistic growth hormone release via dual receptor pathways. GHRH analogs like CJC-1295 stimulate GH secretion by binding growth hormone releasing hormone receptors, while GHRPs stimulate ghrelin receptors. The combined effect produces GH pulse amplitudes 50–100% higher than either compound alone at equivalent doses. Standard stacking protocol: 100–200mcg CJC-1295 (modified GRF) + 200–300mcg ipamorelin administered together, one to two times daily.

Ipamorelin is the preferred GHRP for recovery research because it produces robust GH release without elevating cortisol or prolactin. Side effects seen with GHRP-2, GHRP-6, and hexarelin at supraphysiological doses. Research teams studying body composition often stack CJC-1295 DAC (dosed twice weekly) with daily ipamorelin to maintain baseline GH elevation (from DAC) while amplifying specific pulses (from ipamorelin dosed pre-sleep or post-exercise). This hybrid approach combines dosing convenience with temporal control. You can explore validated peptide combinations like CJC-1295 + Ipamorelin for research applications requiring synergistic GHRH and GHRP pathway activation.

Stacking increases protocol complexity. You're reconstituting two peptides, coordinating injection timing, and managing twice the storage and handling requirements. The payoff is mechanistic: hitting both GHRH and ghrelin receptors simultaneously produces supra-additive effects on pulsatile GH secretion that neither pathway achieves alone. Our recommendation for research teams new to peptide protocols: master single-agent dosing with CJC-1295 DAC first, establish baseline recovery metrics, then introduce stacking variables once you've validated your measurement and reconstitution processes. Rushing into multi-peptide stacks without baseline data makes it impossible to attribute observed effects to specific compounds.

CJC-1295 dosing for recovery isn't guesswork. It's applied pharmacokinetics matched to research endpoints. DAC variants create sustained anabolic environments ideal for continuous processes like nitrogen retention and collagen synthesis. Modified GRF variants create acute metabolic shifts tied to specific pulse windows. Both require temperature-controlled storage, correct reconstitution with bacteriostatic water, and measurement-driven dose titration rather than static adherence to published ranges. If your protocol isn't producing measurable changes after four weeks, the issue is rarely the peptide. It's modification type mismatch, storage failure, or dosing frequency errors that compromise plasma exposure.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 with DAC contains a lysine modification that binds serum albumin, extending plasma half-life to 6–8 days and allowing once or twice weekly dosing at 100–300mcg per injection. Modified GRF (1-29) lacks this modification and has a 30-minute half-life, requiring 100–200mcg dosing two to three times daily to maintain effect. The amino acid sequence at positions 1–29 is identical, but the DAC linker fundamentally changes pharmacokinetics and dosing cadence.

Reconstituted CJC-1295 stored in bacteriostatic water at 2–8°C remains stable for 28 days without measurable potency loss. Peptides reconstituted with sterile water (which lacks benzyl alcohol preservative) must be used within 72 hours. Any temperature excursion above 8°C causes irreversible protein aggregation and 30–40% potency reduction — freezing reconstituted peptides also damages the molecular structure through ice crystal formation.

Dosing CJC-1295 DAC more than twice weekly does not proportionally increase recovery outcomes due to growth hormone receptor saturation kinetics. Research shows that plasma GH concentrations plateau beyond certain dose thresholds, with excess hormone diverted toward lipolysis and glucose dysregulation rather than anabolic processes. The 6–8 day half-life means twice-weekly dosing already maintains sustained plasma levels across the full dosing interval.

Modified GRF (1-29) should be timed to endogenous growth hormone pulse windows for maximum effect: 30–60 minutes before sleep, immediately post-exercise, or during fasted states when endogenous GHRH is already elevated. Research shows slow-wave sleep duration increases by 15–30% when modified GRF is dosed pre-sleep at 100–200mcg. The 30-minute half-life means the peptide must coincide with natural GH pulses to amplify them effectively.

Signs of excessive CJC-1295 dosing include joint stiffness, carpal tunnel symptoms, water retention, and fasting blood glucose elevation above baseline. These indicate sustained growth hormone levels beyond the anabolic threshold, where additional GH drives side effects rather than recovery. Most research protocols stay well below symptom thresholds, but individual response variance means dose optimization requires IGF-1 measurement and recovery endpoint tracking rather than relying on fixed microgram ranges.

Standard reconstitution is 2mg peptide powder to 2mL bacteriostatic water, yielding 1mg/mL (1000mcg/mL) final concentration. This allows a 200mcg dose to be measured as 0.2mL using insulin syringes graduated in 0.01mL increments. You can reconstitute with less water (e.g., 1mL) to double concentration and halve injection volume, but smaller volumes increase measurement error risk during dose drawing.

Research protocols using CJC-1295 DAC typically run 8–16 weeks continuously without cycling, as the peptide does not downregulate GHRH receptors at physiological dose ranges. Modified GRF protocols can run longer due to the pulsatile dosing pattern that mimics endogenous GHRH secretion. Some researchers implement 4-week off periods after 12–16 weeks of continuous use to re-establish baseline measurements, but this reflects study design rather than biological necessity.

Yes — CJC-1295 is frequently stacked with GHRP-class peptides like ipamorelin to create synergistic growth hormone release via dual receptor pathways (GHRH + ghrelin receptors). Standard stacking protocol is 100–200mcg CJC-1295 + 200–300mcg ipamorelin administered together one to two times daily. This combination produces GH pulse amplitudes 50–100% higher than either compound alone, but doubles reconstitution and storage complexity.

If you miss a CJC-1295 DAC dose by fewer than three days, administer the missed dose as soon as possible and resume your regular schedule. If more than three days have passed, skip the missed dose entirely and continue with your next scheduled injection — the 6–8 day half-life means plasma levels remain elevated even with a missed dose. Do not double-dose to compensate, as this creates cumulative plasma concentrations well above intended protocol levels.

Non-response to CJC-1295 in research settings is most often caused by protocol execution errors rather than biological resistance: using modified GRF with a DAC dosing schedule (once weekly), storing reconstituted peptide above 8°C or in sterile water beyond 72 hours, or measuring recovery endpoints at incorrect timepoints relative to dose administration. Verified peptide quality with correct modification type, storage compliance, and measurement timing produces measurable GH elevation in 85–90% of research subjects.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA